Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients
There is a pressing need for further studies to categorize and validate circulating microRNAs (miRs) in breast cancer patients that can be one of the novel strategies for cancer screening and monitoring. The present study is aimed to investigate the expression of the circulating candidate microRNAs...
Gespeichert in:
| Veröffentlicht in: | Scientific reports 2018-12, Vol.8 (1), p.17981-11, Article 17981 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 11 |
|---|---|
| container_issue | 1 |
| container_start_page | 17981 |
| container_title | Scientific reports |
| container_volume | 8 |
| creator | Khalighfard, Solmaz Alizadeh, Ali Mohammad Irani, Shiva Omranipour, Ramesh |
| description | There is a pressing need for further studies to categorize and validate circulating microRNAs (miRs) in breast cancer patients that can be one of the novel strategies for cancer screening and monitoring. The present study is aimed to investigate the expression of the circulating candidate microRNAs after the operation, chemotherapy, and radiotherapy in the non-metastatic breast cancer patients. Tumor tissue and plasma samples were collected from the 30 patients with recently diagnosed Luminal A breast cancer. Control plasma samples were collected from the 10 healthy subjects. A panel of four miRs including miR-21, miR-55, miR-10b, and Let-7a were selected and their expression levels were measured before and after the operation, chemotherapy, and radiotherapy by using Real-Time PCR technique. The plasma expression of the miR-21, miR-155, and miR-10b was significantly increased and the Let-7a plasma expression decreased in the breast cancer patients compromised to the control ones. There was a similar expression pattern of the miRs between the tissue and plasma samples. The plasma levels of the miR-21, miR-155, and miR-10b were significantly down-regulated and the Let-7a plasma level was up-regulated after the operation, chemotherapy, and radiotherapy compromised to the pre-treatment. There was a significant difference in the miR-155 plasma level after the operation, chemotherapy, and radiotherapy compromised with each other. Moreover, there was no significant difference between the plasma levels of the miRs after the radiotherapy compromised to the control cases. The operation, chemotherapy, and radiotherapy led to a more reduction in the oncomiRs and an increase in the tumor suppressor-miRs. It seems that monitoring miRs during treatment might be considered as a respectable diagnostic tool for monitoring of breast cancer patients. |
| doi_str_mv | 10.1038/s41598-018-36321-3 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6299272</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2158542962</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-a7e68ea88f013c1b40406ffd0c31f8106e13673bf5c0cc3d9f9dda15202ff5773</originalsourceid><addsrcrecordid>eNp9kU1vFiEQx4nR2Kb2C3gwJF48FIVhYeFiYhrfkifRGD0TloWWuruswNPEby_Pi7V6kMtMMr_5zwx_hJ4y-pJRrl6VjgmtCGWKcMmBEf4AnQLtBAEO8PBefoLOS7mh7QnQHdOP0QmnQirQcIrq58mW2eI5fiHALvaRCXFM6HCB7TLija-kt9gWXK89XlP1S412wkNMs83ffS44pLwvzmmJNeW4XOEU8JC9LRU7uzif8WprbJ3lCXoU7FT8-TGeoW_v3n69_EA2n95_vHyzIa7ru0ps76XyVqlAGXds6GhHZQgjdZwFxaj0jMueD0E46hwfddDjaJkACiGIvudn6PVBd90Osx9dm53tZNYc29Y_TbLR_F1Z4rW5SrdGgtbQQxN4cRTI6cfWl2rmWJyfJrv4tC0GmgccesZkQ5__g96kbV7aeTtKiQ603AnCgXI5lZJ9uFuGUbPz1Rx8Nc1Xs_fV8Nb07P4Zdy2_XWwAPwBl3X28z39m_0f2F9f_rEo</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2158542962</pqid></control><display><type>article</type><title>Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients</title><source>MEDLINE</source><source>Nature Free</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature OA Free Journals</source><creator>Khalighfard, Solmaz ; Alizadeh, Ali Mohammad ; Irani, Shiva ; Omranipour, Ramesh</creator><creatorcontrib>Khalighfard, Solmaz ; Alizadeh, Ali Mohammad ; Irani, Shiva ; Omranipour, Ramesh</creatorcontrib><description>There is a pressing need for further studies to categorize and validate circulating microRNAs (miRs) in breast cancer patients that can be one of the novel strategies for cancer screening and monitoring. The present study is aimed to investigate the expression of the circulating candidate microRNAs after the operation, chemotherapy, and radiotherapy in the non-metastatic breast cancer patients. Tumor tissue and plasma samples were collected from the 30 patients with recently diagnosed Luminal A breast cancer. Control plasma samples were collected from the 10 healthy subjects. A panel of four miRs including miR-21, miR-55, miR-10b, and Let-7a were selected and their expression levels were measured before and after the operation, chemotherapy, and radiotherapy by using Real-Time PCR technique. The plasma expression of the miR-21, miR-155, and miR-10b was significantly increased and the Let-7a plasma expression decreased in the breast cancer patients compromised to the control ones. There was a similar expression pattern of the miRs between the tissue and plasma samples. The plasma levels of the miR-21, miR-155, and miR-10b were significantly down-regulated and the Let-7a plasma level was up-regulated after the operation, chemotherapy, and radiotherapy compromised to the pre-treatment. There was a significant difference in the miR-155 plasma level after the operation, chemotherapy, and radiotherapy compromised with each other. Moreover, there was no significant difference between the plasma levels of the miRs after the radiotherapy compromised to the control cases. The operation, chemotherapy, and radiotherapy led to a more reduction in the oncomiRs and an increase in the tumor suppressor-miRs. It seems that monitoring miRs during treatment might be considered as a respectable diagnostic tool for monitoring of breast cancer patients.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-018-36321-3</identifier><identifier>PMID: 30568292</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>38/22 ; 45/29 ; 45/56 ; 45/77 ; 45/90 ; 631/67/1347 ; 692/53/2421 ; Adult ; Aged ; Biomarkers, Tumor ; Breast cancer ; Breast Neoplasms - blood ; Breast Neoplasms - diagnosis ; Breast Neoplasms - genetics ; Breast Neoplasms - therapy ; Cancer screening ; Chemotherapy ; Circulating MicroRNA ; Female ; Humanities and Social Sciences ; Humans ; Medical screening ; Metastases ; MicroRNAs ; MicroRNAs - blood ; MicroRNAs - genetics ; Middle Aged ; miRNA ; multidisciplinary ; Neoplasm Grading ; Neoplasm Staging ; Patients ; Plasma levels ; Prognosis ; Radiation therapy ; Science ; Science (multidisciplinary) ; Tumor suppressor genes</subject><ispartof>Scientific reports, 2018-12, Vol.8 (1), p.17981-11, Article 17981</ispartof><rights>The Author(s) 2018</rights><rights>2018. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-a7e68ea88f013c1b40406ffd0c31f8106e13673bf5c0cc3d9f9dda15202ff5773</citedby><cites>FETCH-LOGICAL-c474t-a7e68ea88f013c1b40406ffd0c31f8106e13673bf5c0cc3d9f9dda15202ff5773</cites><orcidid>0000-0002-1147-3335</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299272/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6299272/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30568292$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Khalighfard, Solmaz</creatorcontrib><creatorcontrib>Alizadeh, Ali Mohammad</creatorcontrib><creatorcontrib>Irani, Shiva</creatorcontrib><creatorcontrib>Omranipour, Ramesh</creatorcontrib><title>Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>There is a pressing need for further studies to categorize and validate circulating microRNAs (miRs) in breast cancer patients that can be one of the novel strategies for cancer screening and monitoring. The present study is aimed to investigate the expression of the circulating candidate microRNAs after the operation, chemotherapy, and radiotherapy in the non-metastatic breast cancer patients. Tumor tissue and plasma samples were collected from the 30 patients with recently diagnosed Luminal A breast cancer. Control plasma samples were collected from the 10 healthy subjects. A panel of four miRs including miR-21, miR-55, miR-10b, and Let-7a were selected and their expression levels were measured before and after the operation, chemotherapy, and radiotherapy by using Real-Time PCR technique. The plasma expression of the miR-21, miR-155, and miR-10b was significantly increased and the Let-7a plasma expression decreased in the breast cancer patients compromised to the control ones. There was a similar expression pattern of the miRs between the tissue and plasma samples. The plasma levels of the miR-21, miR-155, and miR-10b were significantly down-regulated and the Let-7a plasma level was up-regulated after the operation, chemotherapy, and radiotherapy compromised to the pre-treatment. There was a significant difference in the miR-155 plasma level after the operation, chemotherapy, and radiotherapy compromised with each other. Moreover, there was no significant difference between the plasma levels of the miRs after the radiotherapy compromised to the control cases. The operation, chemotherapy, and radiotherapy led to a more reduction in the oncomiRs and an increase in the tumor suppressor-miRs. It seems that monitoring miRs during treatment might be considered as a respectable diagnostic tool for monitoring of breast cancer patients.</description><subject>38/22</subject><subject>45/29</subject><subject>45/56</subject><subject>45/77</subject><subject>45/90</subject><subject>631/67/1347</subject><subject>692/53/2421</subject><subject>Adult</subject><subject>Aged</subject><subject>Biomarkers, Tumor</subject><subject>Breast cancer</subject><subject>Breast Neoplasms - blood</subject><subject>Breast Neoplasms - diagnosis</subject><subject>Breast Neoplasms - genetics</subject><subject>Breast Neoplasms - therapy</subject><subject>Cancer screening</subject><subject>Chemotherapy</subject><subject>Circulating MicroRNA</subject><subject>Female</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Medical screening</subject><subject>Metastases</subject><subject>MicroRNAs</subject><subject>MicroRNAs - blood</subject><subject>MicroRNAs - genetics</subject><subject>Middle Aged</subject><subject>miRNA</subject><subject>multidisciplinary</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Patients</subject><subject>Plasma levels</subject><subject>Prognosis</subject><subject>Radiation therapy</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><subject>Tumor suppressor genes</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kU1vFiEQx4nR2Kb2C3gwJF48FIVhYeFiYhrfkifRGD0TloWWuruswNPEby_Pi7V6kMtMMr_5zwx_hJ4y-pJRrl6VjgmtCGWKcMmBEf4AnQLtBAEO8PBefoLOS7mh7QnQHdOP0QmnQirQcIrq58mW2eI5fiHALvaRCXFM6HCB7TLija-kt9gWXK89XlP1S412wkNMs83ffS44pLwvzmmJNeW4XOEU8JC9LRU7uzif8WprbJ3lCXoU7FT8-TGeoW_v3n69_EA2n95_vHyzIa7ru0ps76XyVqlAGXds6GhHZQgjdZwFxaj0jMueD0E46hwfddDjaJkACiGIvudn6PVBd90Osx9dm53tZNYc29Y_TbLR_F1Z4rW5SrdGgtbQQxN4cRTI6cfWl2rmWJyfJrv4tC0GmgccesZkQ5__g96kbV7aeTtKiQ603AnCgXI5lZJ9uFuGUbPz1Rx8Nc1Xs_fV8Nb07P4Zdy2_XWwAPwBl3X28z39m_0f2F9f_rEo</recordid><startdate>20181219</startdate><enddate>20181219</enddate><creator>Khalighfard, Solmaz</creator><creator>Alizadeh, Ali Mohammad</creator><creator>Irani, Shiva</creator><creator>Omranipour, Ramesh</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1147-3335</orcidid></search><sort><creationdate>20181219</creationdate><title>Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients</title><author>Khalighfard, Solmaz ; Alizadeh, Ali Mohammad ; Irani, Shiva ; Omranipour, Ramesh</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-a7e68ea88f013c1b40406ffd0c31f8106e13673bf5c0cc3d9f9dda15202ff5773</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>38/22</topic><topic>45/29</topic><topic>45/56</topic><topic>45/77</topic><topic>45/90</topic><topic>631/67/1347</topic><topic>692/53/2421</topic><topic>Adult</topic><topic>Aged</topic><topic>Biomarkers, Tumor</topic><topic>Breast cancer</topic><topic>Breast Neoplasms - blood</topic><topic>Breast Neoplasms - diagnosis</topic><topic>Breast Neoplasms - genetics</topic><topic>Breast Neoplasms - therapy</topic><topic>Cancer screening</topic><topic>Chemotherapy</topic><topic>Circulating MicroRNA</topic><topic>Female</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Medical screening</topic><topic>Metastases</topic><topic>MicroRNAs</topic><topic>MicroRNAs - blood</topic><topic>MicroRNAs - genetics</topic><topic>Middle Aged</topic><topic>miRNA</topic><topic>multidisciplinary</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Patients</topic><topic>Plasma levels</topic><topic>Prognosis</topic><topic>Radiation therapy</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><topic>Tumor suppressor genes</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Khalighfard, Solmaz</creatorcontrib><creatorcontrib>Alizadeh, Ali Mohammad</creatorcontrib><creatorcontrib>Irani, Shiva</creatorcontrib><creatorcontrib>Omranipour, Ramesh</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Khalighfard, Solmaz</au><au>Alizadeh, Ali Mohammad</au><au>Irani, Shiva</au><au>Omranipour, Ramesh</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2018-12-19</date><risdate>2018</risdate><volume>8</volume><issue>1</issue><spage>17981</spage><epage>11</epage><pages>17981-11</pages><artnum>17981</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>There is a pressing need for further studies to categorize and validate circulating microRNAs (miRs) in breast cancer patients that can be one of the novel strategies for cancer screening and monitoring. The present study is aimed to investigate the expression of the circulating candidate microRNAs after the operation, chemotherapy, and radiotherapy in the non-metastatic breast cancer patients. Tumor tissue and plasma samples were collected from the 30 patients with recently diagnosed Luminal A breast cancer. Control plasma samples were collected from the 10 healthy subjects. A panel of four miRs including miR-21, miR-55, miR-10b, and Let-7a were selected and their expression levels were measured before and after the operation, chemotherapy, and radiotherapy by using Real-Time PCR technique. The plasma expression of the miR-21, miR-155, and miR-10b was significantly increased and the Let-7a plasma expression decreased in the breast cancer patients compromised to the control ones. There was a similar expression pattern of the miRs between the tissue and plasma samples. The plasma levels of the miR-21, miR-155, and miR-10b were significantly down-regulated and the Let-7a plasma level was up-regulated after the operation, chemotherapy, and radiotherapy compromised to the pre-treatment. There was a significant difference in the miR-155 plasma level after the operation, chemotherapy, and radiotherapy compromised with each other. Moreover, there was no significant difference between the plasma levels of the miRs after the radiotherapy compromised to the control cases. The operation, chemotherapy, and radiotherapy led to a more reduction in the oncomiRs and an increase in the tumor suppressor-miRs. It seems that monitoring miRs during treatment might be considered as a respectable diagnostic tool for monitoring of breast cancer patients.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>30568292</pmid><doi>10.1038/s41598-018-36321-3</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-1147-3335</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2045-2322 |
| ispartof | Scientific reports, 2018-12, Vol.8 (1), p.17981-11, Article 17981 |
| issn | 2045-2322 2045-2322 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6299272 |
| source | MEDLINE; Nature Free; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry; Springer Nature OA Free Journals |
| subjects | 38/22 45/29 45/56 45/77 45/90 631/67/1347 692/53/2421 Adult Aged Biomarkers, Tumor Breast cancer Breast Neoplasms - blood Breast Neoplasms - diagnosis Breast Neoplasms - genetics Breast Neoplasms - therapy Cancer screening Chemotherapy Circulating MicroRNA Female Humanities and Social Sciences Humans Medical screening Metastases MicroRNAs MicroRNAs - blood MicroRNAs - genetics Middle Aged miRNA multidisciplinary Neoplasm Grading Neoplasm Staging Patients Plasma levels Prognosis Radiation therapy Science Science (multidisciplinary) Tumor suppressor genes |
| title | Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T08%3A24%3A52IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Plasma%20miR-21,%20miR-155,%20miR-10b,%20and%20Let-7a%20as%20the%20potential%20biomarkers%20for%20the%20monitoring%20of%20breast%20cancer%20patients&rft.jtitle=Scientific%20reports&rft.au=Khalighfard,%20Solmaz&rft.date=2018-12-19&rft.volume=8&rft.issue=1&rft.spage=17981&rft.epage=11&rft.pages=17981-11&rft.artnum=17981&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-018-36321-3&rft_dat=%3Cproquest_pubme%3E2158542962%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2158542962&rft_id=info:pmid/30568292&rfr_iscdi=true |